Another vaccine for group B meningococcal disease has won FDA approval: Novartis’ Bexsero, the agency said late Friday.

Bexsero is the vaccine used on an emergency basis in 2013 to quell a meningitis outbreak on the Princeton University campus and also in a second outbreak centered at the University of California Santa Barbara.

It’s the second group B meningococcal vaccine to receive FDA approval. Last October, it gave the go-ahead to Trumenba, manufactured by Pfizer’s Wyeth subsidiary.

Previous meningococcal vaccines only provided coverage for the A, C, Y, and W serogroups of Neisseria meningitidis.

READ FULL ARTICLE Curated publisher From Medical Page Today